Wada et al. described the significance of time when the combination of anti-CTLA-4 antibody and GM-CSF GVAX vaccine takes place in the Pro-TRAMP prostate cancer model, indicating that anti-CTLA-4 antibody should be given subsequent to vaccination to guarantee synergistical benefits [128]. The gene discussed is CTLA4; the disease is prostate cancer.